Dysregulated expression of long noncoding RNAs has been reported in many types of cancers, indicating that it may play a critical role in tumorigenesis. The long noncoding RNA highly up-regulated in liver cancer (HULC) was first characterized in hepatocellular carcinoma. However, the detailed mechanisms of HULC remain unclear. Here, we demonstrate a novel mechanism by which long noncoding RNA plays oncogenic roles through modulating the phosphorylation status of its interaction protein. First, we validated the markedly increased expression levels of HULC in hepatocellular carcinoma tissues compared to their adjacent noncancerous tissues. Furthermore, up-regulation of HULC was correlated with grading and overall survival. Meanwhile, HULC could promote cell proliferation, migration, and invasion in vitro and inhibit cisplatin-induced apoptosis. Moreover, we show that HULC specifically binds to Y-box binding protein 1 (YB-1) protein both in vitro and in vivo. YB-1 is a major component of translationally inactive messenger ribonucleoprotein particles which keeps mRNA in a silent state. Our study further demonstrated that HULC could promote the phosphorylation of YB-1 protein, which leads to the release of YB-1 from its bound mRNA. As a consequence, translation of silenced oncogenic mRNAs would be activated, including cyclin D1, cyclin E1, and matrix metalloproteinase 3. In addition, we found that HULC promotes the phosphorylation of YB-1 protein mainly through extracellular signal-regulated kinase. Conclusion: We demonstrate that HULC promotes the phosphorylation of YB-1 through the extracellular signal-regulated kinase pathway, in turn regulates the interaction of YB-1 with certain oncogenic mRNAs, and consequently accelerates the translation of these mRNAs in the process of tumorigenesis. (HEPATOLOGY 2017;65:1612-1627 H epatocellular carcinoma (HCC) is the second most common cause of cancer mortality worldwide and is estimated to represent 50% of new cancer cases in China.
H epatocellular carcinoma (HCC) is the second most common cause of cancer mortality worldwide and is estimated to represent 50% of new cancer cases in China. (1) In most cases, HCC arises in cirrhotic livers, and the major cause is related to chronic liver injury caused by viral infections.
Moreover, aflatoxin exposure, alcohol abuse, and metabolic disorders have also been recognized as major risk factors. (2) Hepatocarcinogenesis is believed to be a complex and multistep process involving both epigenetic and genetic alterations that eventually lead to the malignant transformation of hepatocytes. (3) Despite advances in the understanding of the molecular mechanisms underlying HCC and improved treatments, the overall survival time is still limited. Thus, a detailed understanding of the molecular mechanisms involved in HCC is imperative. Long noncoding RNAs (lncRNAs) are a class of noncoding RNA transcripts which are longer than 200 nucleotides and poorly conserved. (4) Although only a few functional lncRNAs have been well characterized so far, they have been shown to play significant regulatory roles in diverse cellular processes. (5) Given the fact that the precise mechanisms by which lncRNAs function still needs to be uncovered, a widely proposed model is that lncRNAs may play roles as signals, decoys, guides, or scaffolds for other regulatory proteins. (6) For example, lncRNA-p21 is a direct target of p53 in response to DNA damage and represses the expression of p53-regulated genes by binding to the heterogeneous nuclear ribonucleoprotein-potassium complex. (7) Additionally, lncRNA-Gas5 binds to the DNA-binding domain of the glucocorticoid receptor by acting as a decoy. (8) Furthermore, lncRNAs can serve as molecular scaffolds; for example, HOTAIR has been shown to bridge between PRC2 and the LSD1/CoREST/REST complex, thus suppressing gene expression. (9, 10) Recently, dysregulated expression of lncRNAs has been reported in many types of cancers, indicating that it may play a critical role in tumorigenesis. Metastasisassociated lung adenocarcinoma transcript 1 has been discovered as a prognostic marker for lung cancer metastasis and acts as a regulator of gene expression. (11) Prostate cancer gene expression marker 1 has been identified as a novel, highly prostate tissuespecific gene and promotes prostate cancer progression. (12) Highly up-regulated in liver cancer (HULC) is strongly overexpressed in HCC. Recently, elevated expression of HULC was also reported in pancreatic cancer, gastric cancer, (13) osteosarcoma, (14) and colorectal carcinomas that metastasize to the liver. (15) Moreover, expression of HULC in plasma can be used as a noninvasive biomarker for the diagnosis and/or prognosis of HCC. (16) Mechanistically, Wang et al. have pointed out that CREB stimulates HULC expression by binding at the core promoter of HULC. (17) Meanwhile, posttranscriptional destabilization of HULC is governed by insulin-like growth factor 2 (IGF2) mRNA-binding protein 1. (18) Elevated HULC promotes hepatoma cell proliferation rate and tumor growth by suppressing p18. (19) In addition, HULC may act as an endogenous sponge, which down-regulates a series of microRNA activities, including those of miR-372 (17) and miR-107. (20) A number of investigations have recently demonstrated that lncRNAs exert their biological function mainly through their interaction proteins. However, the detailed mechanisms remain unclear. Y-box protein-1 (YB-1) is considered to be a multifunctional protein that belongs to the cold-shock domain protein superfamily, which has been highly conserved during evolution. (21) YB-1 participates in a wide range of cellular functions, including transcriptional regulation, mRNA splicing, translational regulation, DNA repair, and stress responses to extracellular signals.
Here, we show that HULC specifically binds to YB-1 protein and accelerates its phosphorylation through extracellular signal-regulated kinase (ERK), which leads to the release of YB-1 from YB-1-mRNA complexes and facilitates the translation of silenced mRNAs, including cyclin D1, cyclin E1, and matrix metalloproteinase 3 (MMP3). As a consequence, HULC enhances the malignant phenotypes of hepatoma cells. This finding demonstrates a novel mechanism by which lncRNA plays an oncogenic role through modulating the phosphorylation status of its interaction protein.
Materials and Methods

TISSUE SAMPLES
HCC tissue samples and adjacent normal liver tissue samples from 41 HCC patients were collected from the Zhongshan Hospital (Shanghai, China). Tissue specimens were immediately frozen in liquid nitrogen after surgery and stored at -80˚C for subsequent analysis. All samples were derived from patients who had not received adjuvant treatment including chemotherapy or radiotherapy prior to the surgery. Written informed consent for research purposes was provided for the patients enrolled in this study.
CELL CULTURE AND TREATMENT
HepG2 and SMMC-7721 cells were purchased from the Cell Culture Center, Chinese Academy of Medical Sciences (Beijing, China). HepG2 cells were grown in Eagle's minimum essential medium, while the SMMC-7721 cell line was maintained in 1640 medium. Both of the cell lines were supplemented with 10% fetal bovine serum (Gibco) at 37 8C. For cisplatin treatment, cells were grown in medium containing 40 lM cisplatin for 6 hours until harvested. For nocodazole (Sigma) treatment, cells were treated with 200 ng/mL nocodazole for the indicated time points. For stimuli and inhibitor treatment, cells were treated with serum starvation for 24 hours and then stimulated with 100 ng/mL epidermal growth factor (EGF) or IGF1 for 2 hours. Cells were also treated with 100 lM LY294002, 5 lM Akt/protein kinase B signaling inhibitor 2 (API-2), 50 lM PD098059, or 25 lM SL0101 for 1 hour prior to stimulation with IGF1 or EGF.
QUANTIGENE ASSAY
Total RNA from tissue samples was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instruction. Specific oligonucleotide probe sets were designed for HULC (Panomics, Fremont, CA), mixed with 10 ng of RNA, and then added to the 96-well capture plate. Hybridization was performed overnight (16 hours) at 55 C, and the plate was then washed with wash buffer followed the manufacturer's instruction. Chemiluminescent signals were then detected by a 96-well plate luminometer. The expression level of HULC in each sample was normalized to actin.
xCELLIGENCE ASSAY
Cell proliferation and migration were measured using the xCELLigence system (Roche), which is a real-time and label-free cell analysis system. For cell proliferation, 2,000 cells in 50 lL culture medium were added to each well for the impedance baseline measurement, and then the final volume was brought up to 150 lL by adding 100 lL culture medium. The E-plates were incubated at 37 8C with 5% CO 2 and monitored on the system at 15-minute intervals for up to 100 hours. For cell migration, cell invasion/migration (CIM) plates were prepared containing 150 lL 20% fetal bovine serum culture medium in the lower well. The upper wells were attached, and 100 lL serum-free Dulbecco's modified Eagle's medium was added per well. The CIM plates were incubated at 37 8C for approximately 1 hour. A baseline impedance reading was taken using the cell-free CIM plates. Cells were then added to the upper wells in serum-free medium to give 2 3 10 4 cells/well. The CIM plates were placed in the xCELLigence system at 15-minute intervals for up to 30 hours.
RNA FLUORESCENCE IN SITU HYBRIDIZATION
A locked nucleic acid (LNA) probe for HULC was synthesized with 3 0 -Cy3 modification, and probe for actin with 5 0 -fluorescein amidite modification was used as a control (Exigon, Woburn, MA). Hybridization was carried out at 60 C with fixed frozen tissue sections or culture cells. Cellular DNA was finally stained with 4 0 ,6-diamidino-2-phenylindole (SigmaAldrich, St. Louis, MO). Fluorescence signals were detected on a Leica TCS SP5 confocal microscope.
RNA PULL-DOWN ASSAY
Biotin-labeled RNA was transcribed in vitro using the MEGAscript T7 Kit with biotin-uridine triphosphate and purified using the MEGAclear Kit according to the manufacturer's instructions, then incubated with whole-cell lysates. Biotin-labeled transcripts and coprecipitated proteins were isolated with streptavidin beads, subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis, and further visualized by silver staining or immunoblotting assay.
RNA IMMUNOPRECIPITATION
RNA immunoprecipitation (RIP) was performed by using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit according to the manufacturer's instructions. Coprecipitated RNAs were extracted 
STATISTICAL ANALYSIS
Statistical analysis was assessed by SPSS 13.0 software (SPSS, Chicago, IL) and GraphPad Prism software (La Jolla, CA). The statistical significance of differences between experimental groups was determined with Student t tests. The v 2 test was used to assess associations between HULC expression and clinicopathologic parameters. Kaplan-Meier survival curves were used. Prognostic factors were evaluated by univariate and multivariate analyses using Cox proportional hazard regression models. Data are presented as mean 6 standard deviation, and each experiment was performed at least three times. Differences were considered statistically significant at P < 0.05.
Results
HIGH EXPRESSION OF HULC IS ASSOCIATED WITH TUMOR GRADE AND POOR PROGNOSIS IN HCC PATIENTS
To validate the elevated expression of HULC in HCC, we first examined HULC expression levels in 40 pairs of liver cancer and their adjacent noncancerous tissues by QuantiGene assay. (23) As expected, we found that the relative expression level of HULC was significantly higher in HCC samples compared with adjacent noncancerous tissues from the same patient (P 5 0.0004; Fig. 1A ). Statistical analysis indicated that high HULC expression was correlated with differentiation grade (P 5 0.022). However, HULC expression did not correlate with age, sex, embolus, or alphafetoprotein. Previous studies have reported that HULC was induced by the viral HBx protein, (19, 24) but our data showed there was no association with hepatitis B virus (HBV) infection (P 5 1.000; Table 1 ).
Additionally, Kaplan-Meier analysis revealed that patients with higher HULC expression had poorer survival (P 5 0.0326; Fig. 1B ). However, HULC expression was not an independent prognostic indicator for overall survival according to the univariate and multivariate survival analyses (Supporting Table S1 ).
Furthermore, we employed the RNA fluorescence in situ hybridization (FISH) assay (25) with 3 0 -Cy3 modification LNA probes for HULC in frozen sections of HCC tissue and adjacent noncancerous tissue. HULC expression in cancer tissues was significantly higher, but the actin expression was similar between tumor and non-tumor samples (Fig. 1C) .
HULC ENHANCES CELL PROLIFERATION BY PROMOTING G 1 /S TRANSITION
Next, we examined HULC expression levels in the HCC cell lines by RT-PCR and found that HULC was highly expressed in HepG2 cells, which was consistent with previous reports (26) (Supporting Fig.  S1A ). In addition, the expression level of HULC was checked in different types of cancer cell lines, including esophageal cancer, colon cancer, and lung cancer cells. Similar to the previous report, HULC was only highly expressed in liver cancer cell lines (Supporting Fig.  S1B ). We also examined the function of HULC in cell proliferation by using the xCELLigence System (27) and found that exogenous expression of HULC promoted cell proliferation, while knocking down HULC . Coprecipitated RNAs were detected by semiquantitative RT-PCR using primers for U6 (row 1) and HULC (row 2). Real-time PCR was also applied to determine the amount of RNA associated with YB-1 immunoprecipitation relative to IgG control. Data are from one of three independent experiments and represent mean 6 standard deviation. (E) A series of truncated versions of HULC was used to perform an RNA pull-down assay, followed by immunoblotting with YB-1 antibody. (F) HepG2 cells were seeded on glass coverslips in six-well plates and then fixed with 4% paraformaldehyde. LNA probes for HULC (red) and a fluorescence-conjugated antibody against YB-1 (green) were used for combined application of RNA FISH and immunofluorescence. The cell nucleus was stained with 4 0 ,6-diamidino-2-phenylindole (blue). Abbreviation: DAPI, 4 0 ,6-diamidino-2-phenylindole; tRNA, transfer RNA.
inhibited the proliferation of hepatoma cells ( Fig. 2A,B) . In addition, cell cycle analysis by flow cytometry showed that knockdown of HULC resulted in an increase of G 1 phase from 54.93% to 61.80% and 65.84%. However, exogenous expression of HULC did not show a significant effect on G 1 phase reduction. To better understand the function of HULC in G 1 /S transition, cell-cycle distribution analyses were conducted with nocodazole, which blocks cells in mitosis.
(28) After 10-hour exposure to nocodazole, remarkable induction of the G 1 population (from 14.35% to 38.25% and 41.39%) was observed in HULC-depleted cells compared with control cells (Fig. 2C) . Meanwhile, exogenous expression of HULC decreased the G 1 population from 29.03% to 18.03% after treatment with nocodazole for 12 hours and from 13% to 5.9% for 16 hours (Fig. 2D) . These results suggest that HULC enhances cell proliferation by promoting G 1 /S transition. To elucidate the possible effects of HULC on cell migration and invasion, we performed real-time migration and invasion assays using the xCELLigence system and found that HULC significantly improved cell migration and invasive abilities (Supporting Fig. S1F,G) . We also treated cells with cisplatin, one of the most active cytotoxic agents for HCC treatment. (29) HULC-depleted cells showed increased apoptosis rate over control cells (Fig. 2E ). These observations suggest that HULC enhances the cellular malignant phenotypes and cell proliferation by promoting G 1 /S transition.
HULC SPECIFICALLY BINDS TO YB-1 PROTEIN
We performed an RNA pull-down experiment in which biotinylated HULC, antisense HULC, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH, two negative controls) were synthesized in vitro and incubated with whole HepG2 cell lysates. There was a specific band associated with HULC (Fig. 3A, red  arrow) . The band specific to HULC was then cut out, digested with trypsin, and subjected to mass spectrometry. Interestingly, the mass spectrometric analysis identified YB-1 as a HULC-interacting protein. We further verified such interaction independently by western blot analysis, and the results showed that YB-1 was clearly detected in HULC pull-down protein complexes but not in antisense HULC or GAPDH (Fig. 3B) .
To confirm the specificity of the YB-1 interaction with HULC, we performed a competition assay by adding gradient concentrations of nonbiotinylated HULC or GAPDH. The interaction between HULC and YB-1 competed with nonbiotinylated HULC in a dose-dependent manner but not transfer RNA (Fig.  3C ). In addition, RIP was performed to validate the interaction between HULC and YB-1. As expected, we observed a significant enrichment of HULC in the YB-1 RIP relative to the immunoglobulin G (IgG) control RIP (Fig. 3D) .
To identify the regions of HULC that are required for the YB-1 interaction, we performed deletionmapping experiments. We found that the region from nucleotides 200 to 300 was mainly responsible for binding to YB-1 (Fig. 3E) . Moreover, subcellular colocalization of HULC and YB-1 was seen by combined application of RNA FISH and immunofluorescent approaches. LNA probes with 3 0 -Cy3 modification for HULC and a fluorescent conjugated antibody against YB-1 were used for this detection (Fig. 3F) . Taken together, the RNA pull-down, RIP, deletion-mapping, and colocalizing assays demonstrate that HULC specifically interacts with YB-1.
HULC PROMOTES THE PHOSPHORYLATION OF YB-1 PROTEIN
In the next step, we investigated the possible biological roles of the interaction between HULC and YB-1 protein. However, neither exogenous expression nor knocking down the endogenous expression of HULC affected the protein level of YB-1 (Fig. 4A,B) . Considering that the physical interaction of HULC and YB-1 mainly took place in the cytoplasm, where YB-1 protein activates translation of silent mRNAs after phosphorylation, we examined whether YB-1 phosphorylation status might be altered by HULC. Exogenous expression of HULC increased the YB-1 phosphorylation, while knocking down HULC reduced the phosphorylation level of YB-1 (Fig.  4C,D) . Additionally, we found that phosphorylation of YB-1 was elevated in a dose-dependent manner following transfection of HULC plasmids (Fig. 4E) .
Furthermore, we used a cell-permeable peptide (CPP) that has been reported to prevent endogenous YB-1 S102 phosphorylation through molecular docking. (30) The CPP and its scrambled control peptides were synthesized with fluorescein isothiocyanate to monitor cell absorption. Both the scrambled control and CPP rapidly entered the cells within 4 hours (Supporting Fig. S3A ). We then demonstrated that the enhanced phosphorylation level of YB-1 in exogenous HULC cells was abolished by adding the CPP (Fig. 4F) .
Following this, we constructed YB-1 mutant plasmid at the S102 phosphorylation site (pEGFP-YB-1 S102A ). We then cotransfected the wild-type, mutant plasmids and control plasmid (pEGFP-C1) with small interfering HULC and small interfering NC, respectively. As expected, we found that the phosphorylation level of exogenous YB-1 was significantly higher in control cells than HULC-depleted cells after transfection with wild-type construct but disappeared after transfection with mutant construct (Fig. 4G) .
ERK MEDIATES THE PHOSPHORYLATION OF YB-1 PROMOTED BY HULC
As YB-1 phosphorylation could be induced by certain growth stimuli, (31) HepG2 cells were treated with IGF, EGF, 20% fetal bovine serum, or transforming growth factor b1. The phosphorylation of YB-1 was significantly induced by IGF and EGF but not by 20% fetal bovine serum or transforming growth factor b1 (Supporting Fig. S2D) .
It has been shown that the cold shock domain of YB-1 could be phosphorylated by Akt at Ser102 and that disruption of this specific site inhibits tumor cell growth. (32) Additionally, ERK has been reported to phosphorylate YB-1 protein, thus affecting the binding of YB-1 to the vascular endothelial growth factor heart rate reduction coding strand in vitro. (33) Ribosomal S6 kinase (RSK), a direct substrate of ERK, was also determined to phosphorylate the serine 102 residue in breast cancer cells. (31) To distinguish which pathway was influenced by HULC, we pretreated HepG2 cells with inhibitors of the phosphoinositide 3-kinase (PI3K)-Akt pathway (LY294002 and API-2), ERK (PD098059), and RSK (SL0101), combined with additions of IGF and EGF, respectively. Significant activation of the Akt pathway was achieved by adding IGF, as reflected by induced phosphorylation of Akt (Fig. 5) . As expected, the activation of phosphorylated Akt was substantially reduced in the presence of the inhibitor LY294002, but this inhibitor slightly reduced the phosphorylation of YB-1. Considering that LY294002 was actually the inhibitor of PI3K, we subsequently used a specific inhibitor of Akt kinase, API-2, which does not inhibit the activation of PI3K or pyruvate dehydrogenase kinase 1. (34) To our surprise, the phosphorylation level of YB-1 dramatically increased, although API-2 successfully abrogated the phosphorylation of Akt.
Furthermore, the addition of EGF strongly activated ERK/RSK cascades, which was abolished by the inhibitor PD098059. Strikingly, the phosphorylation of YB-1 was significantly reduced in the presence of the inhibitor PD098059. In addition, the inhibitor
FIG. 5. HULC regulates phosphorylation of YB-1 protein through ERK. (A)
HepG2 cells were treated with serum starvation for 24 hours and then stimulated with 100 ng/mL EGF or IGF-I for 2 hours. Cells were also treated with 100 lM LY294002, 1 lM API-2, 50 lM PD098059, or 25 lM SL0101 for 1 hour prior to stimulation with IGF-I or EGF. Whole-cell extracts were analyzed by immunoblotting with total YB-1, phosphorylated YB-1, total Akt, phosphorylated Akt, total ERK, phosphorylated ERK, total RSK, and phosphorylated RSK. Actin was used as a loading control. (B) After transfection with an siRNA pool targeting HULC or control siRNA, HepG2 cells were treated as described in (H). Whole-cell extracts were analyzed by immunoblotting with phosphorylated YB-1 and total YB-1. Actin was used as a loading control. (C) RNA pull-down assay was applied as described above, and the proteins were then subjected to immunoblotting assays with antibodies to ERK and YB-1. (D) Cell lysates were prepared for coimmunoprecipitation. Coimmunoprecipitation with YB-1 antibody was performed, and precipitates were then subjected to immunoblotting assays with antibodies to ERK, phosphorylated ERK, and YB-1. Abbreviation: p-, phosphorylated; WB, western blot. SL0101 had little effect on the phosphorylation of YB-1. We noticed that inhibition of the PI3K-Akt pathway could activate ERK/RSK cascades, while inhibition of ERK also activated the phosphorylation of Akt. The remarkably increased phosphorylation of YB-1 after using API-2 may be caused by the complementary induction of activated ERK. The different phosphorylation levels of YB-1 in HULC knockdown cells and control cells were abolished after treating cells with PD098059 but not with LY294002 and SL0101 (Fig. 5B) . Therefore, it appears that YB-1 phosphorylation promoted by HULC is mediated through activation of the ERK pathway.
Additionally, the RNA pull-down assay demonstrated a physical interaction of HULC with ERK (Fig. 5C ). We further demonstrated that there is a functional crosstalk between HULC and the ERK-YB-1 pathway. Depletion of HULC through a small interfering RNA (siRNA) approach greatly reduced the interactions of YB-1 with phosphorylated ERK and total ERK (Fig. 5D) . It can therefore be generally stated that HULC regulates the phosphorylation of YB-1 protein through ERK.
HULC ACCELERATES THE TRANSLATION OF YB-1 BOUND ONCOGENIC mRNAs
YB-1 protein has been reported to relieve translational repression of bound mRNAs after its phosphorylation, which in turn regulates cell proliferation, cell cycle progression, and metastasis. (35) Given the fact that HULC promotes YB-1 phosphorylation, it is speculated that HULC may modulate certain mRNA translations. To test this hypothesis, we performed RIP assays to analyze the interaction between YB-1 and certain mRNAs. As expected, YB-1 protein, but not phosphorylated YB-1, could specifically bind to these tumor-related mRNA genes, including CCND1, CCNE1, and MMP11 (Fig. 6A,B) , indicating that these target mRNAs were released from YB-1 after its phosphorylation. Furthermore, YB-1 protein appeared to bind a much higher amount of mRNA in HULC knockdown cells than in control cells. We then sought to determine whether HULC increases the protein level of these YB-1 target genes. Knockdown of HULC led to the reduced expression of cyclin D1, cyclin E1, and MMP11 but not actin (Fig. 6C) . These results go along with the finding of reduced interaction of certain mRNAs after knockdown of HULC. Meanwhile, we found that the levels of these mRNAs in HULC knockdown cells showed little difference (Fig. 6D) .
HULC REGULATES THE PHOSPHORYLATION OF OTHER SUBSTRATES OF ERK
Considering that ERK is a major kinase of the mitogen-activated protein kinase family that can activate many proteins, we examined whether HULC might affect the phosphorylation status of other ERK substrates. RSK, also known as p90 ribosomal S6 kinase, is a direct substrate of ERK, (36) which has been excluded from the kinases that can phosphorylate YB-1. To our surprise, HULC also affected the phosphorylation of RSK (Fig. 6E,F) . Additionally, the RNA pull-down assay demonstrated a physical interaction of HULC with RSK (Fig. 6G) . In further support of this observation, depletion of HULC through the siRNA approach greatly reduced the interactions of RSK with ERK (Fig. 6H) . Meanwhile, we found that exogenous expression of HULC increased the phosphorylation of c-fos, another substrate of ERK (Supporting Fig.  S3B ). Collectively, these observations suggest that HULC regulates the phosphorylation of other substrates of ERK.
HULC PROMOTES CELL PROLIFERATION THROUGH YB-1 PHOSPHORYLATION
In order to examine the function of YB-1 phosphorylation in cell proliferation, we used PD098059, an inhibitor of ERK, and the CPP to inhibit or block phosphorylation. As expected, YB-1 phosphorylation inhibition by adding PD098059 or CPP abolished the enhanced proliferation rate promoted by HULC (Fig.  7A,B) . Likewise, we found that the mutant construct abolished the enhanced proliferation rate promoted by HULC (Supporting Fig. S3C ).
Given the fact that HULC is overexpressed in HCC, we are tempted to propose that HULC acts as a scaffold for the phosphorylation of YB-1 and that ERK is recruited to activate YB-1 in the presence of HULC expression. The phosphorylation of YB-1 decreases the interaction of oncogenic mRNAs with YB-1 and accordingly accelerates the translation of these mRNAs, such as cyclin D1, cyclin E1, and MMP11. As a consequence, HULC thus enhances the malignant phenotypes of hepatoma cells (Fig. 7C) . After transfection with an siRNA pool targeting HULC or control siRNA in HepG2 cells, total RNA was prepared for analyzing the expression of HULC, cyclin D1, cyclin E1, MMP11, and actin transcripts with real-time PCR and proteins were subjected to immunoblotting assays with antibodies to cyclin D1, cyclin E1, MMP11, and actin. (E) HepG2 cells were transfected with siHULC or control siRNA. (F) SMMC-772 cells were transfected with either pseudo-complementary DNA3.1 or pseudo-complementary DNA3.1-HULC. After 48-hour transfection, proteins from (E) and (F) were subjected to SDS-PAGE (10%). Antibody against phosphorylated RSK protein and total RSK was used in the western blot analysis, and actin (43 kDa) was used for a loading control. (G) RNA pull-down assay was applied as described above, and the proteins were then subjected to immunoblotting assays with antibodies to ERK and RSK. (H) Cell lysates were prepared for coimmunoprecipitation. Coimmunoprecipitation with ERK antibody was performed, and the precipitates were then subjected to immunoblotting assays with antibodies to ERK and RSK. Abbreviations: p-, phosphorylated; pcDNA, pseudo-complementary DNA.
YB-1 protein through ERK. As a consequence, the phosphorylation of YB-1 protein leads to its release from silenced oncogenic mRNAs and in turn accelerates the translation of these mRNAs in the process of tumorigenesis. Based on these findings, we propose a HULC working model, illustrated in Fig. 7C , which also demonstrates a novel mechanism by which lncRNA plays an oncogenic role through modulating the phosphorylation status of its interaction protein.
Consistent with the previous reports, HULC is significantly up-regulated in HCC tissues. Moreover, we show remarkably increased expression of HULC in situ with LNA probes in frozen sections. Interestingly, high HULC expression is correlated with high differentiation grade, which indicates a crucial role of HULC in the development of HCC. HBV infection is the first risk factor that triggers liver carcinogenesis. (37) However, recent reports have presented conflicting opinions regarding whether HULC is induced by HBV infection. (18, 19, 24) Our data in the current study showed no direct association with HBV infection. Considering the limited size of the patient cohort, we may have to enlarge the sample size to exclude the possibility that HULC elevation is correlated with viral infection in future studies. Indeed, elevated expression of HULC was observed in other non-HBV-related cancers, suggesting that up-regulation of HULC may be also caused by other factors.
In this study, we verified the function of HULC in cell proliferation by using a new real-time, label-free cell analysis system and found that HULC promotes the proliferation of hepatoma cells. We further show that HULC promotes cell proliferation by accelerating cell-cycle progression. Cell-cycle distribution analyses show remarkable changes of G 1 phase after exogenous expression or knocking down HULC, especially in cells treated with nocodazole, which blocks cells in mitosis. (28) These results suggest that HULC enhances cell proliferation through promoting G 1 /S transition. The G 1 /S phase transition is controlled by the activation of a set of specific cyclin-dependent kinases (CDKs). Mistakes in this process lead to unrestrained cell proliferation, which may result in genomic instability and ultimately facilitate malignant transformation. (38) In addition, our study shows that HULC can inhibit cisplatin-induced apoptosis. Apoptosis resistance is a hallmark of human cancer and contributes to therapeutic resistance. (39) It has been shown that lncRNAs exert their biological function mainly by binding and modulating the functions of proteins. (7, 9) Although IGF2 mRNA-binding protein 1 has been identified as a HULC binding protein, which governs its posttranscriptional destabilization, (18) the specific proteins modulated by HULC with direct interaction are still unknown. Our study identifies YB-1 as a specific HULC-interacting protein through combined application of RNA pull-down assay and mass spectrometry. This interaction is further supported by RIP, competition assay, and deletion-mapping experiments. Moreover, we confirmed the subcellular colocalization of HULC and YB-1 by RNA FISH and immunofluorescent approaches.
YB-1 is a multifunctional protein which participates in DNA reparation and transcription, mRNA splicing, and translation. (40) It is now well established that YB-1 is a member of the cold-shock protein superfamily, which contains a cold-shock domain motif that binds to both DNA and RNA. (21) We speculate that YB-1 may associate with HULC through its cold-shock domain motif. Interestingly, YB-1 protein has been reported to be overexpressed in many types of cancers, including HCC, breast cancer, colon cancer, gastric cancer, and prostate cancer. (41) (42) (43) Consistent with these findings, YB-1 is considered an oncoprotein which regulates multiple proliferation pathways, overrides cell-cycle check points, and promotes genomic instability, angiogenesis, and metastasis. (44) We next identified that HULC affects the phosphorylation status rather than the total protein level of YB-1. Furthermore, we demonstrated that HULC regulates the phosphorylation of YB-1 protein through ERK. In addition, we found that HULC increases the phosphorylation of RSK by enhancing its interaction with ERK. Based on these findings, we speculate that HULC may serve as a scaffold that recruits ERK and its substrates together, thus promoting the phosphorylation of target proteins. As the mitogen-activated protein kinase/ERK pathway plays an important role in the initiation and regulation of cellular processes, such as proliferation, survival, and differentiation, (45) our study indicates that HULC may modulate the phosphorylation function of ERK by acting as a scaffold in the process of tumorigenesis.
It is worth mentioning that the mechanisms of lncRNA function in regulating cellular processes are complicated and diversified. Several lncRNAs have been implicated in regulating transcriptional or posttranscriptional level, but the lncRNAs that regulate signal transduction at the posttranslational level are still unclear. To our knowledge, only a few lncRNAs have been reported to participate in the phosphorylation process. NKILA, a nuclear factor-kappa B interacting lncRNA, directly masks the phosphorylation motifs of IkappaB and then inhibits the phosphorylation of IkappaB. (46) Another cytoplasmic lncRNA, lnc-DC, directly binds to signal transducer and activator of transcription 3 and prevents its dephosphorylation by small heterodimer partner 1. (47) NRON, an lncRNA in a large cytoplasmic RNA-protein scaffold complex, regulates the dephosphorylation of nuclear factor of activated T cells. (48) Likewise, these are all cytoplasmic lncRNAs, indicating the existence of a class of lncRNAs that regulate protein modifications.
YB-1 protein has been reported to act as a predominant component of translationally inactive messenger ribonucleoprotein particles, while phosphorylation at Ser-102 relieves YB-1 from the bound mRNAs and activates the translation of silent mRNA species. (35) Our data demonstrate that HULC decreases the interaction of mRNAs with YB-1 and consequently accelerates their translation, including cyclin D1, cyclin E1, and MMP11. The eukaryotic cell cycle is regulated by the activation of different CDK/cyclin complexes. (49) Cyclin D1 forms a complex with CDK4 or CDK6, while cyclin E1 forms a complex with CDK2. (50) Both of these cyclins are required for cell cycle G 1 /S transition. Considering that HULC promotes the phosphorylation of YB-1 and accelerates the translation of cyclin D1 and cyclin E1, we speculate that HULC may promote G 1 /S transition through increasing the protein levels of these two cyclins. This concept is further supported by observations that inhibition of YB-1 phosphorylation by adding PD098059 to cells abolishes the enhanced proliferation promoted by HULC.
In conclusion, we demonstrate that the lncRNA HULC promotes the phosphorylation of YB-1 protein through ERK and consequently accelerates the translation of oncogenic mRNAs. Our study demonstrates that lncRNA regulates the phosphorylation of cellular protein and provides insight into the complex biological functions of lncRNA.
